

**From:** [redacted]  
**To:** [redacted]; [redacted]; [redacted]  
**Cc:** [redacted]  
**Subject:** RE: URGENT: Questionnaire on possible needs for investigational therapeutics to treat Covid-19 patients DL. 7.4. COB  
**Date:** woensdag 8 april 2020 11:46:43  
**Attachments:** [image002.jpg](#)  
[image003.png](#)

Hartelijk dank voor je terugkoppeling, [redacted]  
 Vriendelijke groet,  
 [redacted]

**From:** [redacted]  
**Sent:** dinsdag 7 april 2020 19:10  
**To:** [redacted]; [redacted]; [redacted]; [redacted]  
**Cc:** [redacted]  
**Subject:** FW: URGENT: Questionnaire on possible needs for investigational therapeutics to treat Covid-19 patients DL. 7.4. COB

Beste collega's,

Bedankt voor jullie input vandaag en vorige week op de EU aanbestedingsvraag voor een vijftal experimentele COVID-geneesmiddelen. Ter informatie hieronder onze reactie richting Europese Commissie.

De keuze voor het poeder i.p.v. het concentraat is na overleg met het CBG.

Vriendelijke groet,

[redacted]

**Ministerie van Volksgezondheid, Welzijn en Sport**

Directie Geneesmiddelen en Medische Technologie

Parnassusplein 5 | 2511 VX | Den Haag | [redacted]

Postbus 20350 | 2500 EJ | Den Haag

M: [redacted] | E: [redacted] [@minvws.nl](mailto:info@minvws.nl)

[www.rijksoverheid.nl](http://www.rijksoverheid.nl)



**Van:** [redacted]

**Verzonden:** dinsdag 7 april 2020 18:56

**Aan:** 'S [redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>' <[redacted]>

[redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>

**CC:** [redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>; [redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>;

[redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>; [redacted] <[\[redacted\]@ec.europa.eu](mailto:[redacted]@ec.europa.eu)>

**Onderwerp:** RE: URGENT: Questionnaire on possible needs for investigational therapeutics to treat Covid-19 patients DL. 7.4. COB

Dear colleagues,

Thank you for your email.

Please be informed that we only wish to join this EU procurement procedure for **remdesivir** and not for any of the other four products (i.e. kaletra, (hydroxy)chloroquine, interferon beta and tocilizumab), see attachment.

Please note that we only filled in the details related to our need for remdesivir as the purpose or necessity of the other information at this stage of the process is unclear to us. In case Commission considers this type of information essential, kindly further clarify.

Kind regards,

5.1.2e

**Ministry of Public Health, Welfare and Sport**

Directorate Medicines and Medical Technology

Parnassusplein 5 | 2511 VX | The Hague | The Netherlands | 5.1.2e

Postbox 20350 | 2500 EJ | The Hague | The Netherlands

M: 5.1.2e | E: 5.1.2e @minvws.nl

[www.rijksoverheid.nl](http://www.rijksoverheid.nl)

---

**Van:** 5.1.2e @ec.europa.eu <SANTE-LUX-JOINT-PROCUREMENT-SECRETARIAT@ec.europa.eu>

**Verzonden:** dinsdag 7 april 2020 11:42

**Aan:** 5.1.2e @ec.europa.eu

**CC:** 5.1.2e @ec.europa.eu; 5.1.2e @ec.europa.eu;

5.1.2e @ec.europa.eu; 5.1.2e @ec.europa.eu

**Onderwerp:** URGENT: Questionnaire on possible needs for investigational therapeutics to treat Covid-19 patients DL. 7.4. COB

**Urgentie:** Hoog

Dear colleagues,

You had informed us previously about possible needs for investigational therapeutics to treat Covid-19 patients. Many thanks for this.

We have found that countries submitted their needs in different units or packaging sizes, not always in line with available formulations.

**We therefore need to ask you again to submit your interest in these investigational therapeutics to treat COVID-19 patients in the attached questionnaire.**

Please also indicate interest for ACTEMRA (Tocilizumab) that was not included in the first list, if DG SANTE can information share or not with the relevant the companies and if you are in touch with companies yourself or not. We have had first discussions with a series of companies this week.

**Please reply to us by close of business today, 7 April 2020.**

Thank you very much in advance.

Kind regards,

**SANTE Joint Procurement Agreement Team**



European Commission | Health and Food Safety | Crisis Management and Preparedness in Health  
LU-2920 Luxembourg | HTC

5.1.2e @ec.europa.eu